注射用盐酸头孢吡肟细菌内毒素检查法

目的 :研究注射用盐酸头孢吡肟对细菌内毒素检查试验的干扰情况 ,并建立其细菌内毒素检查的方法。方法 :参照中国药典 2 0 0 0年版二部附录XIE细菌内毒素检查法和附录XIXF细菌内毒素检查法应用指导原则进行试验。结果 :供试品在 3.33mg·ml-1稀释浓度下无干扰作用。结论 :获得了可靠的实验数据和结果并建立了本品的细菌内毒素检查法。     

应用鲎试剂检测吡拉西坦葡萄糖注射液中的细菌内毒素

建立吡拉西坦葡萄糖注射液的细菌内毒素检查法.参照<中国药典>2005年版二部附录"细菌内毒素检查法"进行干扰试验和结果判断.样品的最大无干扰浓度为16mg·ml-1,用浓度为6.4mg·ml-1的样品液进行细菌内毒素检查,结果无干扰作用.本品可以用细菌内毒素检查法代替家兔热原检查法.     

细辛脑注射剂细菌内毒素检查法研究

目的 建立细辛脑注射剂的细菌内毒素检查法。方法 按中国药典2010年版二部附录ⅪE细菌内毒素检查法进行实验和结果判断。对不同厂家生产的供试品进行干扰试验和细菌内毒素检查。结果 浓度为0.1 mg·mL^-1细辛脑注射剂溶液对鲎试剂与细菌内毒素的凝集反应有干扰作用,经稀释后可排除干扰。结论 本品最大不干扰浓度为0.05 mg·mL^-1,可采用细菌内毒素检查法进行质量控制。     

鱼金注射液细菌内毒素检查方法的研究

目的　对鱼金注射液进行细菌内毒素检查研究 ,建立检查鱼金注射液中细菌内毒素的试验方法。方法　采用《中国药典 2 0 0 0年版》附录细菌内毒素检查方法。结果　干扰试验结果表明 :用标示灵敏度为 0 5Eu·ml-1的鲎试剂 ,将鱼金注射液稀释至 6倍时 ,对细菌内毒素检查无干扰作用。结论　用细菌内毒素检查法检查鱼金注射液中细菌内毒素是可行的。可用细菌内毒素检查法 (凝胶法 )代替家兔热原检查法控制其热原。     

苯唑西林钠细菌内毒素检查法的建立

目的: 建立苯唑西林钠细菌内毒素检查法.方法: 参照中国药典2000年版二部附录XIE 细菌内毒素检查法和附录XIXF 细菌内毒素检查法应用指导原则,采用凝胶法进行干扰试验.结果: 本品的最大不干扰浓度为2.5mg*ml-1.结论: 本品适用于细菌内毒素检查法.     

阿莫西林钠细菌内毒素检查法的可行性探讨

目的建立阿莫西林钠细菌内毒素检查的方法.方法按<中国药典>2000年版二部附录细菌内毒素检查法和细菌内毒素检查法应用指导原则进行试验.结果本品在5.0mg·mL-1稀释浓度以下无干扰作用,L=0.2EU·mg-1.结论本品可用细菌内毒素检查法代替热原检查法.     

奥沙利铂注射液细菌内毒素检查方法的研究

目的:对奥沙利铂注射液进行细菌内毒素检查的干扰试验,并建立其细菌内毒素检查方法.方法:参照2000年版<中国药典(二部)>附录细菌内毒素检查法和细菌内毒素检查法应用指导原则进行试验.结果:通过干扰试验确证,按拟定标准检验,本品1个规格共3批供试品的细菌内毒素检查结果均符合规定.结论:本品1 mL含奥沙利铂2 mg的供试品及其稀释液对细菌内毒素检查无干扰.可用鲎试验法代替家兔热原检查法控制奥沙利铂注射液的热原.     

乳酸环丙沙星注射液细菌内毒素检查法的研究

目的建立乳酸环丙沙星细菌内毒素检查的方法。方法按《中国药典》2000年版二部附录细菌内毒素检查法和细菌内毒素检查法应用指导原则进行试验。结果本品在5.0mg/ml稀释浓度以下无干扰作用,L=0.42EU/ml。结论本品可用细菌内毒素检查法代替热原检查法。     

盐酸莫西沙星葡萄糖注射液细菌内毒素检查方法验证

目的：建立盐酸莫西沙星葡萄糖注射液的细菌内毒素检查方法。方法：按《中国药典〉2010年版二部附录XIE细菌内毒素检查法进行,用不同厂家的鲎试剂对不同批号的盐酸莫西沙星葡萄糖注射液进行干扰试验和细菌内毒素检查。结果：用稀释剂I将本品原液稀释至20倍,用灵敏度为0．06EU·ml^-1的鲎试剂检查细菌内毒素,无干扰作用,按拟定标准检验,该品种3批样品细菌内毒素检查结果均符合规定。结论：本品可用细菌内毒素检查法检查,其细菌内毒素的限值（L）为0．75EU·mg^-1。     

鱼腥草注射液细菌内毒素检查法的建立

目的　探讨鱼腥草注射液的细菌内毒素检查方法。方法　按《中国药典》2 0 0 0年版 (二部 )附录收载的细菌内毒素检查法和指导原则进行试验。结果　经确定本品细菌内毒素限值L为 3EU ml,将样品稀释 6倍 ,用灵敏度为 0 5EU ml的鲎试剂检查无干扰作用。结论　鱼腥草注射液可用细菌内毒素检查法取代家兔热原法     

Readmissions for treatment for alcoholism

First admissions and readmissions for alcoholism have risen steeply in recent decades. This study looked at readmission histories for four cohorts of alcoholics first admitted to inpatient psychiatric treatment in 1967-68, 1973, 1977 or 1979. Over the twelve years the first cohort was observed, alcoholics on average spent 254 days in treatment and had 2.14 alcohol-related readmissions. However the distributions were very skewed: 50% stayed less than 92 days and 45.6% had no readmissions at all. All four cohorts yielded similar results over comparable time periods and all showed markedly skewed distributions reflecting the diversity of readmission histories among alcoholics. Policy decisions about alcoholism inpatient treatment must take account of this diversity.     

Prospects for MEK inhibitors for treating cancer

Introduction: The MAPK pathway is a signaling network that plays a key role in many normal cellular processes and in a large number of human malignancies. One of its effectors, MEK, is essential for the carcinogenesis of different tumors. In recent years, several drugs able to inhibit MEK have been assessed in clinical trials. Trametinib has recently become the first MEK inhibitor licensed for cancer treatment (advanced melanoma).

Areas covered: We comprehensively review the safety and clinical efficacy of the family of MEK inhibitors, either alone or in combination with other drugs. We discuss data ranging from the Phase III trial of trametinib in melanoma to the most recent drugs with early signs of antitumor activity. In addition, we explain the reasons for the unsuccessful results of the early trials with MEK inhibitors and provide a view of their role in cancer treatment in forthcoming years.

Expert opinion: MEK inhibitors are a potentially safe and active treatment option for the treatment of many human malignancies. The information provided by a large series of studies currently ongoing will be very valuable in order to optimize their use. Adequate selection of patients is crucial for achieving successful results with these compounds.     

Potential directions for drug development for osteoarthritis

Background: Osteoarthritis (OA) is a frustrating disease for both patient and physician because neither cause nor cure is known and there are currently no disease-modifying drugs. Objective: To review current therapeutic approaches as well as new findings regarding OA pathoetiology that could form the basis of future direction for the development of drugs to prevent or slow down disease progression. Methods: After reviewing disease progression in human OA, as demonstrated by histological analyses, the reasons for cartilage erosion are explored and possible therapeutic approaches are highlighted. Results/conclusions: OA may be an epigenetic disease. This new concept can explain many aspects of the disease and provide reasons why therapeutic approaches until now have met with little success.     

Projections for insulin treatment for diabetics

The evolution of insulin treatment of diabetes has dramatically changed the natural course of this disease. Modern recombinant DNA technology has brought about many new insulin analogues with improved pharmacokinetics, resulting in better glycemic control. In addition, improved insulin delivery systems, such as insulin pumps and pens, have been introduced to provide convenience and to enhance patient compliance. Efforts are currently being devoted to developing noninvasive insulin formulations, such as oral and pulmonary insulin. A number of products are at different stages of clinical trials. Meanwhile, the quest for a permanent cure for diabetes continues. The frontier of diabetes research has gone through a period of substantial expansion, with the emergence of new areas that include gene therapy, islet cell transplantation and diabetic vaccine. Technological breakthroughs, such as recombinant DNA, nanotechnology, microarray-aided genomics and proteomics, will provide more profound insights into the pathogenesis, and the immunological and biological basis of diabetes. Our growing knowledge in these areas will ultimately contribute to the discovery of preventive methods against or a cure for this disease.     

我院门诊调剂室实施规范化管理的措施

目的:加强门诊调剂室规范化管理,保证药品质量,确保患者用药安全。方法:建立包括管理细则、工作程序、岗位分工及各类药品管理制度在内的系统的管理制度和操作规程。结果与结论:通过实施制度化、规范化管理,有利于规范人员行为,减少药患纠纷,提高患者信任度和满意度,保证患者的用药安全。